Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Preclinical and pilot clinical studies of docetaxel chemoradiation for stage III non-small-cell lung cancer
Yuhchyau Chen; Kishan J. Pandya; Ollivier Hyrien; Peter C. Keng; Therese Smudzin; Joy Anderson; Raman Qazi; Brian Smith; Thomas J. Watson; Richard H. Feins; et al. (Profiled Author: Richard H Feins)
International Journal of Radiation Oncology Biology Physics. 2011;80(5):1358-1364.Abstract
Purpose: Local and distant failure rates remain high despite aggressive chemoradiation (CRT) treatment for Stage III non-small-cell lung cancer. We conducted preclinical studies of docetaxel's cytotoxic and radiosensitizing effects on lung cancer cell lines and designed a pilot study to target distant micrometastasis upfront with one-cycle induction chemotherapy, followed by low-dose radiosensitizing docetaxel CRT. Methods and Materials: A preclinical study was conducted in human lung cancer cell lines NCI 520 and A549. Cells were treated with two concentrations of docetaxel for 3 h and then irradiated immediately or after a 24-h delay. A clonogenic survival assay was conducted and analyzed for cytotoxic effects vs. radiosensitizing effects of docetaxel. A pilot clinical study was designed based on preclinical study findings. Twenty-two patients were enrolled with a median follow-up of 4 years. Induction chemotherapy consisted of 75 mg/m 2 of docetaxel and 75 mg/m 2 of cisplatin on Day 1 and 150 mg/m 2 of recombinant human granulocyte colony-stimulating factor on Days 2 through 10. Concurrent CRT was started 3 to 6 weeks later with twice-weekly docetaxel at 10 to 12 mg/m 2 and daily delayed radiation in 1.8-Gy fractions to 64.5 Gy for gross disease. Results: The preclinical study showed potent cytotoxic effects of docetaxel and subadditive radiosensitizing effects. Delaying radiation resulted in more cancer cell death. The pilot clinical study resulted in a median survival of 32.6 months for the entire cohort, with 3- and 5-year survival rates of 50% and 19%, respectively, and a distant metastasis-free survival rate of 61% for both 3 and 5 years. A pattern-of-failure analysis showed 75% chest failures and 36% all-distant failures. Therapy was well tolerated with Grade 3 esophagitis observed in 23% of patients. Conclusions: One-cycle full-dose docetaxel/cisplatin induction chemotherapy with recombinant human granulocyte colony-stimulating factor followed by pulsed low-dose docetaxel CRT is promising with regard to its antitumor activity, low rates of distant failure, and low toxicity, suggesting that this regimen deserves further investigation. © 2011 Elsevier Inc.
PMID: 20708854 PMCID: PMC3268047
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Jin Wang; Shaomin Tian; Robby A. Petros; Mary E. Napier; Joseph M. DesimoneJournal of the American Chemical Society. 2010;132(32):11306-11313.
Xiao Bai; Stefan Sandukas; Mark Appleford; Joo L. Ong; Afsaneh RabieiJournal of Biomedical Materials Research - Part B Applied Biomaterials. 2012;100 B(2):553-561.
Danielle R. Mercatante; James L. Mohler; Ryszard KoleJournal of Biological Chemistry. 2002;277(51):49374-49382.
Appears in this Document